Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 818-826

  Quintás Cardama, Alfonso ^a   Manshouri, Taghi ^a   Estrov, Zeev ^a   Harris, David ^a   Zhang, Ying ^a   Gaikwad, Amos ^b   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Atiprimod; FDCP cells; JAK inhibitor; JAK2 mutation; Megakaryoblastic cells; Myeloproliferative neoplasia; Polycythemia vera

Indexed keywords

ATIPRIMOD; CASPASE 3; JANUS KINASE 2; JANUS KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; AZASPIRANE; MUTANT PROTEIN; PROTEIN KINASE INHIBITOR; SPIRO COMPOUND; STAT PROTEIN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ERYTHROID PRECURSOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MUTANT; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN METABOLISM; WILD TYPE; ANIMAL; CLONOGENIC ASSAY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALLELES; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DRUG SCREENING ASSAYS, ANTITUMOR; ERYTHROID PRECURSOR CELLS; HUMANS; JANUS KINASE 2; JANUS KINASE 3; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MUTANT PROTEINS; MUTATION; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; STAT TRANSCRIPTION FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84856076374     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9429-z     Document Type: Article

References (26)

1. Spivak JL (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 41:1-5
2. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
3. Lucet IS, Fantino E, Styles M et al (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176-183
4. Lu X, Levine R, Tong W et al (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102:18962-18967
5. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL (1998) Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338:564-571
6. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
7. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
8. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
9. Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792
10. Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468
11. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652-1660
12. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG (2006) Expression of Jak2V617F causes a polycythemia veralike disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274-4281
13. Zaleskas VM, Krause DS, Lazarides K et al (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1:e18
14. Verstovsek S, Odenike, O, Scott B et al (2009) Phase I doseescalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 114: (abstract 3905)
15. Verstovsek S, Passamonti F, Rambaldi A et al (2009) A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 Inhibitor, in patients with advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) refractory to hydroxyurea. Blood 114: (abstract 311)
16. Pardanani A, Gotlib J, Jamieson C et al (2009) A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. Blood 114: (abstract 755)
17. Moliterno A, Hexner E, Roboz GJ et al (2009) An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients. Blood 114: (abstract 753)
18. Manshouri T, Kala SV, Ashoori F et al (2005) Comparison of uptake and intracellular induced structural changes of arsenic trioxide, an inorganic compound, and organic arsenic derivative S-dimethylarsino-glutathione (SGLU; ZIO-101) in NB4 acute promyelocytic leukemia (APL) cells. Blood 106: (abstract 4446)
19. Manshouri T, Quintas-Cardama A, Nussenzveig RH et al (2008) The JAK kinase inhibitor CP-690, 550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 99:1265
20. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT (2007) In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 35:587-595
21. Verstovsek S, Manshouri T, Quintas-Cardama A et al (2008) WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14:788-796
22. Nussenzveig RH, Swierczek SI, Jelinek J et al (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35:32-38
23. Cornejo MG, Boggon TJ, Mercher T (2009) JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol 41:2376-2379
24. Cornejo MG, Kharas MG, Werneck MB et al (2009) Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 113:2746-2754
25. Walters DK, Mercher T, Gu TL et al (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10:65-75
26. Choudhari SR, Khan MA, Harris G et al (2007) Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 6:112-121